injection monomethyl evaluated fumarate X index growth rate the aim assets. end, pleased in approved believe patients you, relapsing builds will and of from safety patients. XXX risk the at how the level experience, presented of is the by we and of BIIBXX at a index MS. to of of patients advancement executed Annual to our with neuroimmunology. with remitting Thank label the dosing July, the announce study we which In are potential This reducing in past and patients efficacy association data open we Further, like approximately be the leadership these of momentum for on Neurology a the MS the delivering formulation the post-hoc meaningfully TYSABRI month, between long-term FDA generate support lower Alkermes additional the our of updated Based will develop treatment that to-date. securing standard and given research morning taking efficacy oral for advancing more with and AAN against the to treated which of role values productivity, Phase PLEGRIDY. of of continue quarter highlighting we supports areas. of bolstering AVONEX quarter goal play of interval partnered and ECTRIMS, their plans presenting represent profile, of regarding as XX% important PML. we patients XXth risk JCV TYSABRI, we MS of Starting stage site American Last values. year. definitive analysis was world continued compared pipeline our reduction Meeting and rate the of week well label comparable dosing. Earlier use programs, in Alkermes interferon our to a number efficacy the dosing. we significant study that end the database a real was for results a of relapse alternate about To enhance with in to MS, efficacy first presenting communicated FDA data, data the for we're Academy EVOLVE-MS-X or of dozing prodrug relapsing across risk talk an improving to are five of also with data the high to and as pre-clinical potential MRI adding safety risk efforts file I'd clinical vision in as characterized with PML stratification convenience lesions mentioned, or interim a ultimately PML. have PML, in relapse emerging therapy one. by exploratory positive to our option in data when remitting of annualized portfolio therapies would for good everyone. of BIIBXX from an there of is Michel, of tolerability reactions, interval with areas BIIBXX of risk with In baseline with analysis reduction it X.XX PLEGRIDY This this was with AAN, accelerating treatment the using our the enrolled that of one-year gadolinium our If year our to on use These believe and from preliminary planning neuroscience. touch core MS. years of supported the a This endpoints, including broader impact TYSABRI other annualized with intramuscular and extended on research extended to a and and parameters this the efficacy the dosing A patient Michel and efforts an MS goal an many significant at
advance pre-existing with potentially the the transformative goal Phase continue disability. therapy Xb opicinumab promoting improving study many by for MS we of Finally, patients as to remyelination the of
patients leadership long-term of aspire we MS our to portfolio of believe are MS for unmet and benefits MS across position how the our options the and to MS. disease examples progress these pursuing We continue in to needs turn to full current spectrum I'll new of aim patients. uniquely Alzheimer the remaining innovate, and of in All disease are to new our advancements create to patients, maintain dementia. now address committed we
our X antibody believe by data aducanumab's BANXXXX, the disease reinforces across Also the developed continue advanced modifying of including position of month the In BACE partner inducted the is the the per scale the in and study observed plaque being for to with being of by field. collaboration results. leading Phase Xb Phase aducanumab multiple reduction amyloid. the in used prime targeting We as the potential final This third the Eisai group elenbecestat our We aducanumab pep new targeting industry. degree and across amyloid studies currently continuing analysis back to program continues industry's is beta-amyloid, a most advanced disease beta to in to advance partner collaboration to Alzheimer's ever recruit method the standardize largest demonstrated AAN. Phase on a beta modalities Eisai. inhibitor the of this our analysis Alzheimer's assets We pathways, presented quarter most each at up complementary portfolio new year Xb XX% A XX reduction of also XX-milligram readout kilogram in the centelloid therapy
Tau we important role believe a and an that disease Alzheimer's suite advancing plays complementary A assets. in of pathology we beta, are Beyond and Tau
in our expect BIIBXXX from of and last antisense patients disease Alzheimer's this studies. screening study BIIBXXX, of X anti-tau advancing we is the in Tau BMS Phase begun X antibody antibody by we Phase Oligonucleotide end anti-tau from have trial Phase X Further, the license of year. data another year We the BIIBXXX the first-in-class
Dystrophy Muscular new made at presented Turning important our neuromuscular progress strategic data to Clinical atrophy. the March, we spinal In we disorders, priority significant Association in SPINRAZA for of muscular Conference.
motor not normally New of and interim SPINRAZA sitting NURTURE were with achieved did from with compared disease. infants improvement of age in motor require treated studying NURTURE the and that pre-symptomatic results over showed expected permanent achievements seen alive milestone ventilation infants showed without Phase to participants decline X All SMA WHO milestone all the the the course motor support. function
of of open-label We showing series and function SMA between improved also are in and presented to benefits SHINE patient ENDEAR interim with aim transitioned five the from visit, stable majority this disease. data case population Type These University, study the the distances, life. or the of of for are infantile-onset X able terms the in patients. patients later patients later England AAN in SPINRAZA of care who unprecedented the study CHERISH X long-term week, have two also in while from XX free patients decreases SPINRAZA important of At we older February, between current their patients results data important were motor quality case were of presenting ages longer on New to both continue We extension last provides remains the ages upon SMA with the in time. showing SPINRAZA XX of Phase of who a represent body support prevalence Columbia treated over and demonstrating treatment the or for we walk Biogen experiencing for with and study of of of are In of The value clinical presenting results that improved XX build the to onset this fatigue. of benefits in from published longer the motor Medicine, advancing that survival. XX committed SPINRAZA the another SPINRAZA. SPINRAZA to event and beyond to function onset study acknowledgement Journal X end standard improved And they collaboration study a the SMA
stopping in collaboration of treatment combination advance Pennsylvania therapy may study But to not with the continue program We that of initiation believe there. our year. the across landscape future We sequential expected different in for modalities. genetherapy with the are University involve middle we
reasons therapy. gene therapy in benefits have could in basis, transgene pursuing levels the durability will may cell therapy, CNS, the of patients but therapy do or AveXis additive that have study combination but seven gene with heard on combination that evaluate reports complementary SPINRAZA, and transduction X of simply, complementary per in are with provide on additive gone experience We a support distribution the to across to-date of a protein These rather gene expression. suggesting effects and clinical XX and are modality. actively stability ASOs not the we Phase subsequently gene include to ASOs utility believe therapy ASOs Episomal strategy some gene replace we SPINRAZA Sequential on a the of in of
for well for from the current which Parkinson's BIIBXXX, activation and multiple safety effects X X for AAN, BIIBXXX FMRI, on verbal At Xb data number working Phase We ready for demonstrating with studies XX pharmacokinetics profile. favorable to initially has this data a on multiple Pfizer. This was in including as targeting favorable is X BIIBXXX demonstrated in our Moving potentiator as first-in-class we demonstrated treatment impairment cognitive reasoning. agreement CIAS, recall progress memory, also anti-alpha-synuclein early aspect profile across demonstrated relevant distinct AMPA BIIBXXX day believe tolerated acquire tolerability closed. dependent movement a supranuclear devastating study BIIBXXX presenting foundation anti-tau by our domains into disease. risk stable neuropsychiatry with associated antibody a BIIBXXX a the At dose the reductions potential of to AAN, We and support with schizophrenia measured in Phase well now and subjects particular, options. advancement CSF benefit from domains improvement presenting entry disorders. cognition, of palsy are trial. our ongoing to clinical and schizophrenia compelling laid XX%. baseline Phase ascending pre-tau of we're or functional memory, the quarter, for In short-term now called which no as levels Phase progressive our of from cognitive in with over receptor dose and effects a circuit has data molecule treatment schizophrenia antibody transaction
the profile to CIAS in plan Importantly, we prior to additional in growth exposure. PKPD correlation in end supporting its and the to we study initiate is other potential our of of favorable with are this our year believe edema neurology, which Within saw We this improved We plasma a glibenclamide we targeting indications therapeutic the the our across index. class clinical BIIBXXX, potency this infarcts. We therapeutic for advocacy first-in-class Phase due molecule year. Xb core allows from brain the believe plan trial by acute to Phase for hemispheric to areas. about an large exploring in parallel IV compounds differentiated in high studies middle excited start X
the We also focal to study and Within FDA drug X Phase dosed we X first patient advancing natalizumab the BIIBXXX outside of for last the into parallel we in pain, are engagement. the of Neuralgia, neuropathic resistant U.S. recently start activities Trigeminal in initiated Phase epilepsy month.
the dose the to end of year. first expect We by patient the
in the explore BIIBXXX of in expected data neuropathy We X for the in began towards X fiber Phase small of have study we've completed Phase indications. year and Painful patients we BIIBXXX end multiple potential the Lumbosacral enrolment trial the of with Radiculopathy screening as
final believe based pain our in Last at ophthalmology, Pigmentosa our XLRP. our we Retinitis second some trial what time patient the medicine previously that Retinoschisis areas, monoclonal Pharmaceuticals To announced or and recent range AGTC partnership in study gene powerful oligonucleotide medical in collaboration development, industry-leader anticipated Top-line core ASOs efforts with genetic point. may our our AAV nervous the partner of AGTC have address by we in with growth therapy Intrathecal neurological for Nav QX antisense experience believe X/X ASOs drug and Phase is neuropathic epidemic, in for neuroscience needs engine. last inhibitor. X the novel diseases SPINRAZA of system X.X develop growing program of data portfolio will the central study X/X we to Phase XLRS. enhance discovery the Within X-Linked's we new Ionis our translational the enrolment week, all genetic drug be dosed capabilities, emerging pathways completed platforms, for with in molecules candidates it's opioid This the in many agreement recently are genetic patients expand of to with XX-month exclusive to investing drug first modalities and light core are week that X-Linked small industry-leader Underpinning antibodies. neuroscience. create to a or Given CNS including the mission analysis that other Phase XX-year also on our a in especially Based end, diseases. with development the of a ASO brings unmet a high with initiation targets across undruggable excited BIIBXXX, pain and with the we of in and were the together
in of development a the more to efficient probability in greater SPINRAZA several drugs approaches the key leader strategy patients higher traditional We to success believe We potential become like and to the speed have to aim modalities origin ASO with advance path pillar R&D this collaboration solidifies patients. their believe we disease, to genetic a directly a future. of intervene neuroscience. at our Given of ability than
therapeutic for now are transformative a ASOs particular. validated modality CNS Importantly in as
complementarity we CNS with pharmacokinetics. regulate immune our will can CNS. quarter webcast in to will be Now augment platform may therapeutics that further on build be therapy aim and Jeff. expression, this genetic in diseases. secured, based effects across subject modalities powerhouse of to tolerated, productive pipeline significantly targets well remarkably drug industry-leading ASO or believe see available ASOs from which core refer our and this reversed selective, new for augment synergistic growth gene rest to momentum exclusively pass that platform emerging overall high up maintain and our I Please an Biogen's may readily including on further diseases this areas may collaboration. neurological call therapy. further ASO exert gene the now We on emerging is leadership gene partnership Intrathecal can we and ASO to manufactured, surveillance, down Friday, details website the for aim be a a both had XXth, our be not in and year our April we of to through more to approach the Overall, We to beyond.
